Bicalutamide

Other Notes Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of rare and unique chemicals. Sigma-Aldrich does not collect analytical data for this product.

1 1 4 4-TETRAETHYLPIPERAZINEDIIUM DIBROMIDE-

2 2-DIETHYL-N(1) N(3)-BIS(4-METHYLPHENYL)MALONAMIDE-

2 2-DIMETHYLSUCCINIMIDE-

2-METHYLCINCHONINAMIDE

General description ZooMAb &#174: antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb &#174: antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and

General description ZooMAb &#174: antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb &#174: antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Application Bicalutamide (CDX) has been used as an androgen receptor (AR) antagonist in prostate, bladder cancer cell lines and human fetal skeletal muscle cells. It has also been used as a supplement in RPMI 1640 for culturing androgen-independent

Application Bicalutamide (CDX) has been used as an androgen receptor (AR) antagonist in prostate, bladder cancer cell lines and human fetal skeletal muscle cells. It has also been used as a supplement in RPMI 1640 for culturing androgen-independent

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the